Key result
Venous thromboembolism rates in cancer patients vary between 0.5% and 20%, with primary thromboprophylaxis using low-molecular-weight heparin recommended postoperatively but debated in outpatients.
This review highlights the importance of VTE risk stratification in cancer patients and notes that while postoperative LMWH prophylaxis is recommended, its use in ambulatory chemotherapy patients remains controversial.
No takes yet. Share an insight, caveat, or question.
Requires individualized VTE risk assessment in cancer; leaves open optimal outpatient LMWH strategies.
Pabinger et al. (2015) conducted a review in Venous thromboembolism in cancer. Thromboprophylaxis with low-molecular-weight-heparin (LMWH) was evaluated. Venous thromboembolism rates in cancer patients vary between 0.5% and 20%, with primary thromboprophylaxis using low-molecular-weight heparin recommended postoperatively but debated in outpatients.
Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context: